John Oyler, Founder & CEO of BeiGene, at the US-China Biopharma Innovation and Investment Summit in Shanghai on October 23, 2018; Credit: Endpoints News, PharmCube
BeiGene scores first China OK with PD-1 — to be manufactured by Boehringer Ingelheim
On December 17, 2018, Junshi Biosciences notched the landmark approval for a made-in-China PD-(L)1 checkpoint inhibitor by Chinese regulators. Barely a year later, the fourth …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
